{
  "chapter": "Endocrinology-Diabetes Mellitus-Ii",
  "questions": [
    {
      "q_no": 1,
      "question": "A 60-year-old male with type 2 diabetes comes with symptoms such as flushing, nausea, and palpitations after consuming alcohol. What is the mechanism of action of the drug likely causing these symptoms?",
      "options": {
        "A": "Inhibits hepatic gluconeogenesis",
        "B": "Inhibits the breakdown of GLP-1",
        "C": "Blocks the reabsorption of glucose in PCT",
        "D": "Closes ATP-sensitive potassium channels of the pancreas"
      },
      "correct_answer": "D",
      "explanation": "of a disulfiram-like reaction. This reaction can occur with first-generation sulfonylureas, which stimulate insulin release by closing ATP-sensitive potassium channels in pancreatic beta cells. Drug Class Sulfonylureas Examples First Generation: Chlorpropamide, Tolbutamide Second Generation: Glipizide, Glyburide, Glimepiride Mechanism of Action Acts on ATP-sensitive potassium channels: Closes K+ channels in pancreatic beta cell membrane → cell depolarizes → insulin release via increased Ca2+ influx Indications Drug of choice for patients where metformin is contraindicated It can be added in combination with other hypoglycemic drugs or insulin Side Effects Hypoglycemia Weight gain Disulfiram-like reaction (first-generation sulfonylureas only) Longer-acting Side effects of 1st generation sulfonylurea (Chlorpropamide): cholestatic jaundice, SIADH, and disulfiram-like reaction. Contraindications Avoid in acute porphyria Increased risk of hypoglycemia in renal failure Hepatic dysfunction Inhibits hepatic gluconeogenesis (Option A): This mechanism is associated with metformin and does not cause these symptoms. Inhibits the breakdown of GLP-1 (Option B): This pertains to DPP-4 inhibitors, which do not lead to the described reactions. Blocks the reabsorption of glucose in PCT (Option C): This action refers to SGLT2 inhibitors and does not relate to the symptoms presented. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3111",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 2,
      "question": "A 65-year-old woman with poorly controlled diabetes mellitus presents to the emergency department with fever, facial pain, and a black necrotic eschar on her nasal turbinates. A CT scan shows sinus involvement and possible extension to the brain. What is the most appropriate initial management for this patient?",
      "options": {
        "A": "Oral antifungal therapy",
        "B": "Immediate surgical debridement and intravenous amphotericin B",
        "C": "Intravenous antibiotics only",
        "D": "Observation and supportive care"
      },
      "correct_answer": "B",
      "explanation": "possible central nervous system involvement, immediate surgical debridement is essential to remove necrotic tissue and control the infection. Intravenous amphotericin B is the first-line antifungal treatment that targets the causative organisms, significantly improving the patient's chances of survival. Infections in Diabetes Mellitus Diabetes mellitus (DM) increases susceptibility to opportunistic infections. Focused infections: Rhino-cerebral mucormycosis (RCM) Acute emphysematous cholecystitis Pyelonephritis Rhino-Cerebral Mucormycosis (RCM) Aspect Details Overview Severe fungal infection affecting nasal passages, sinuses, and brain. Causative Agent Primarily caused by Rhizopus oryzae , associated with uncontrolled DM and diabetic ketoacidosis (DKA). Pathophysiology Begins in nasal turbinates; progresses rapidly due to angioinvasive nature, causing tissue necrosis and vascular thrombosis. Clinical Manifestations Fever, facial pain, swelling, nasal discharge, necrotic eschar. Diagnosis Imaging studies and histopathological examination. Treatment Immediate antifungal therapy (e.g., amphotericin B) and aggressive surgical debridement. ACUTE EMPHYSEMATOUS CHOLECYSTITIS Aspect Details Overview Severe gallbladder inflammation with gas formation in the wall; more common in diabetics. Pathophysiology Gas-forming bacteria cause gallbladder wall necrosis; hyperglycemia exacerbates infection. Symptoms Abdominal pain, fever, signs of sepsis. Diagnosis Imaging (ultrasound/CT) showing gas in the gallbladder wall. Treatment Surgical intervention (cholecystectomy) and antibiotic therapy. Pyelonephritis Aspect Details Overview Kidney infection is often caused by uropathogenic bacteria, a significant risk for diabetics. Pathophysiology Increased susceptibility to urinary tract infections (UTIs) leading to ascending pyelonephritis. Symptoms Flank pain, fever, chills, dysuria. Diagnosis Urinalysis and imaging studies if complications arise. Treatment Antibiotics based on culture and sensitivity; hospitalization may be necessary for severe cases. Oral antifungal therapy (Option A): Oral antifungal therapy is insufficient for the severity of rhino-cerebral mucormycosis and does not address the need for urgent intervention. Intravenous antibiotics only (Option C): Intravenous antibiotics alone are not appropriate, as this is a fungal infection requiring antifungal therapy. Observation and supportive care (Option D): Observation and supportive care are not adequate for this life-threatening condition. Prompt intervention is necessary to reduce mortality risk. Reference: https://insightsimaging.springeropen.com/articles/10.1186/s13244-021-01109-z https://www.ncbi.nlm.nih.gov/books/NBK557429/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 3,
      "question": "A 55-year-old woman with a 10-year history of type 2 diabetes presents for a routine eye examination. On examination, she is found to have microaneurysms, retinal haemorrhages, and cotton wool spots. What is the most effective management option for her symptomatic foveal oedema?",
      "options": {
        "A": "Pan-retinal laser photocoagulation",
        "B": "Intravitreal anti-VEGF injections",
        "C": "Corticosteroid injections",
        "D": "Routine observation and follow-up"
      },
      "correct_answer": "B",
      "explanation": "by retinal thickening and fluid accumulation in the macula. This condition can lead to visual impairment and requires prompt treatment to preserve vision. Anti-VEGF therapy has been shown to be more effective than laser treatment for symptomatic foveal oedema in diabetic macular oedema. Diabetic Retinopathy Common Ophthalmic Finding : A prevalent condition in patients with diabetes. Visual Impairment : One of the leading causes of visual impairment in working-age individuals in developed countries. Prevalence : Increases with the duration of diabetes. Pathogenesis: High Blood Sugar Levels : Cause capillary occlusion. Vascular Endothelial Growth Factor (VEGF) : Stimulated by capillary occlusion. Leads to: Increased capillary permeability, causing retinal oedema. Angiogenesis, resulting in new vessel formation. Clinical Features: Clinical Feature Description Detection Capillary occlusion visible only on retinal angiography. Microaneurysms Form on occluded capillaries, leaking fluid and blood. Oedema and Haemorrhages Caused by leakage; lipids precipitate to form exudate. Capillary Changes Occluded capillaries turn white and disappear. Retinal Ischaemia Larger patches form as more capillaries occlude. New Vessels Grow at the border of diseased and non-diseased retina due to increased VEGF from ischaemia. Intraretinal Microvascular Abnormalities (IRMAs) Form from partially perfused capillaries. Venous Beading Develops in retinal veins (multiple diffuse swellings). Flame Haemorrhages Horizontal streaky haemorrhages in the retinal nerve-fibre layer. Cotton Wool Spots Located in the nerve-fibre layer, usually found nasal to the optic disc. Management: Proliferative Diabetic Retinopathy : Untreated can lead to vitreous haemorrhage and retinal detachment. Pan-retinal Laser Photocoagulation : Preserves vision if applied early. Diabetic Macular Oedema : Intravitreal injection therapy is now preferred. Anti-VEGF injections are more effective than laser treatment, often requiring monthly injections. Pan-retinal laser photocoagulation (Option A) : While effective for proliferative diabetic retinopathy, it is not the first-line treatment for symptomatic foveal oedema. Corticosteroid injections (Option C) : While they may have some benefit, anti-VEGF injections are typically preferred in current clinical practice for treating diabetic macular oedema. Routine observation and follow-up (Option D) : This option is not appropriate for symptomatic foveal oedema, as timely intervention is necessary to prevent vision loss. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1174- 1177",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 4,
      "question": "A 55-year-old male with a 15-year history of type 2 diabetes presents for routine evaluation. He has poorly controlled blood sugar levels, and reports increased urination. Urinalysis reveals microalbuminuria. Which of the following management strategies is most crucial in slowing the progression of diabetic nephropathy in this patient?",
      "options": {
        "A": "Strict glycemic control using insulin therapy",
        "B": "Aggressive blood pressure control using ACE inhibitors",
        "C": "Dietary modification to reduce protein intake",
        "D": "Initiation of statin therapy regardless of cholesterol levels"
      },
      "correct_answer": "B",
      "explanation": "IIIIII Correct answer: B) Aggressive blood pressure control using ACE inhibitors Explanation: Aggressive blood pressure control using ACE inhibitors is crucial in managing diabetic nephropathy because it significantly reduces glomerular hyperfiltration and protein leakage, which are key factors in kidney damage progression. ACE inhibitors not only lower blood pressure but also provide protective effects on renal function, making them the first-line treatment in patients with diabetes and nephropathy. Diabetic Nephropathy Aspect Details Definition Serious complication of type 1 and type 2 diabetes; leads to end-stage renal failure in 20-50% of patients. Pathology Damage to small blood vessels (diabetic microangiopathy); characterized by capillary basement membrane thickening, increased permeability, and matrix accumulation. Key Factors Hyperglycemia activates the renin-angiotensin system. Prolonged hyperglycemia causes inflammation and fibrosis. Progression Early hyperfiltration declines over ~10 years; proteinuria develops, reaching nephrotic range by ~14 years. Risk Factors Poor glycemic control, long diabetes duration, other microvascular complications, ethnicity (Asians, Pima Indians), pre-existing hypertension, family history. Diagnosis Microalbuminuria detected via albumin-to-creatinine ratio; overt nephropathy diagnosed with macroalbuminuria (>300 mg/24 hrs). Management Goals Slow kidney damage progression; manage cardiovascular risk. Management Strategies Blood pressure control: ACE inhibitors or ARBs. Glycemic control: strict management. Cardiovascular risk management: address smoking, hypertension, and consider statin therapy. Monitoring Regular monitoring of electrolytes and renal function when using ACE inhibitors/ARBs; alternatives for those intolerant. Strict glycemic control using insulin therapy (Option A) : While important, it is not the most immediate strategy for slowing nephropathy progression compared to blood pressure management. Dietary modification to reduce protein intake (Option C) : While this can be a part of management, it does not have as significant an impact as blood pressure control in this context. Initiation of statin therapy regardless of cholesterol levels (Option D) : Statins are important for managing cardiovascular risk but are not specifically aimed at slowing the progression of nephropathy. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 757-759",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 5,
      "question": "A 60-year-old male with a 15-year history of diabetes presents with numbness and tingling in his feet. On examination, he shows diminished vibration sensation in a \"glove and stocking\" distribution and has absent ankle reflexes. Which of the following features is most characteristic of diabetic neuropathy?",
      "options": {
        "A": "Distal muscle weakness with atrophy of the interosseous muscles",
        "B": "Thickening of the Schwann cell basal lamina",
        "C": "Acute onset of unilateral symptoms",
        "D": "Presence of significant sensory loss in the hands"
      },
      "correct_answer": "B",
      "explanation": "neuropathy. It reflects the underlying metabolic disturbances associated with prolonged diabetes, contributing to nerve degeneration. Diabetic Neuropathy Aspect Details Prevalence 50–90% of people with diabetes; 15–30% develop painful neuropathy Pathological Features Axonal degeneration (myelinated/unmyelinated fibers) Thickened Schwann cell basal lamina Patchy demyelination Abnormal intraneural capillaries Classification Somatic : Symmetrical polyneuropathy (sensory, distal), Asymmetrical polyneuropathy (motor, proximal), Mononeuropathy Visceral : Autonomic dysfunction (various systems) Common Manifestations Symmetrical Sensory Polyneuropathy : Paresthesia, pain, burning sensations, abnormal gait Asymmetrical Motor Neuropathy : Muscle weakness, pain, weight loss, absent reflexes Autonomic Neuropathy : Affects visceral systems Gastroparesis Symptoms Chronic nausea, vomiting of undigested food, abdominal pain, early satiety Management Glycemic control (intensive insulin therapy) Anticonvulsants (gabapentin, pregabalin) Tricyclic antidepressants (amitriptyline, imipramine) Other antidepressants (duloxetine) Topical treatments (capsaicin) Opiates (tramadol, oxycodone) Membrane stabilizers (mexiletine) Antioxidants (alpha-lipoic acid) Diabetic Foot Complications Risk of ulcers from neuropathy/peripheral vascular disease; management includes preventative care and treatment tailored to ulcers Distal muscle weakness with atrophy of the interosseous muscles (Option A) : While muscle weakness can occur, it is more characteristic of asymmetrical motor neuropathy rather than the typical presentation of diabetic neuropathy. Acute onset of unilateral symptoms (Option C) : Diabetic neuropathy usually presents with symmetrical symptoms, not acute unilateral onset. Presence of significant sensory loss in the hands (Option D) : While sensory loss can occur, the \"glove and stocking\" pattern is more typical for the lower extremities in diabetic neuropathy. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 758-761.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 6,
      "question": "Which of the following mechanisms best explains the development of insulin resistance in individuals with obesity and type 2 diabetes?",
      "options": {
        "A": "Increased glucose uptake in peripheral tissues",
        "B": "Reduced gluconeogenesis in the liver",
        "C": "Free fatty acid competition with glucose for oxidation in muscle",
        "D": "Increased release of insulin-sensitive kinases"
      },
      "correct_answer": "C",
      "explanation": "muscles, contributing to insulin resistance and metabolic dysfunction. Hyperlipidemia in Diabetes Mellitus (DM) Dyslipidemia in DM Elevated small dense LDL, triglycerides Decreased HDL Part of metabolic syndrome and insulin resistance Causes of Insulin Resistance Cause Mechanism Obesity & Central Adiposity Visceral fat releases free fatty acids (FFAs) that interfere with glucose metabolism. Adipokines from Adipose Tissue Hormones released by fat cells alter insulin sensitivity. Visceral Fat & Liver Portal vein drainage from visceral fat impacts liver insulin sensitivity and gluconeogenesis. Physical Inactivity Reduces insulin-sensitive kinases Promotes FFA buildup in muscles Increases insulin resistance, even in individuals with similar obesity levels Management of Hyperlipidemia in DM Guidelines for Statin Therapy Recommendation 10-year cardiovascular risk ≥ 20% Start statin therapy All patients with DM aged >40 years Statins recommended regardless of cholesterol levels Increased glucose uptake (Option A) : Insulin resistance reduces, not increases, glucose uptake. Reduced gluconeogenesis (Option B): Insulin resistance promotes gluconeogenesis, worsening hyperglycemia. Increased release of insulin-sensitive kinases (Option D) : Insulin resistance is linked to decreased kinase activity, especially with physical inactivity. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 730, 731, 743",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 7,
      "question": "Which of the following best describes the mechanism of action of Acarbose?",
      "options": {
        "A": "Increases insulin secretion from pancreatic beta cells",
        "B": "Inhibits alpha-glucosidase enzymes, delaying carbohydrate absorption",
        "C": "Stimulates glucose uptake in peripheral tissues",
        "D": "Enhances insulin sensitivity in the liver and muscles"
      },
      "correct_answer": "B",
      "explanation": "reducing post-meal glucose spikes. Acarbose: Mechanism of Action : Inhibits alpha-glucosidase enzymes in the gut, delaying the digestion and absorption of carbohydrates. Administration : Taken with each meal to reduce post-prandial blood glucose and modestly improve glycemic control . Combination Therapy : It can be combined with sulphonylureas for enhanced glucose regulation. Side Effects : Flatulence Abdominal bloating Increases insulin secretion from pancreatic beta cells (Option A): Describes the mechanism of sulfonylureas, not Acarbose. Stimulates glucose uptake in peripheral tissues (Option C): Refers to drugs like metformin, which increase peripheral glucose uptake. Enhances insulin sensitivity in liver and muscles (Option D): Describes thiazolidinediones, which improve insulin sensitivity. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 747",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 8,
      "question": "A 65-year-old female with a long-standing history of type 2 diabetes mellitus presents to her physician for a routine follow-up. During the visit, she reported recurrent urinary tract infections and has experienced difficulty controlling her blood glucose levels. Which medication is contraindicated in this patient?",
      "options": {
        "A": "Metformin",
        "B": "Canagliflozin",
        "C": "Liraglutide",
        "D": "Glipizide"
      },
      "correct_answer": "B",
      "explanation": "an increased risk of urinary tract infections (UTIs). Given the patient's recurrent UTIs, this medication is contraindicated to prevent further complications. Drug Class Sodium-glucose co-transporter 2 (SGLT2) Inhibitors Examples Canagliflozin Dapagliflozin Empagliflozin Mechanism of Action Blocks reabsorption of glucose in the proximal convoluted tubule, promoting the excretion of sodium and glucose in urine Indications Reduce progression of chronic kidney disease (CKD) Diuretic effect, leading to sodium loss Reduces systolic blood pressure (SBP) by 3-6 mmHg Cardiorenal advantage CHF to decrease mortality with or without DM Side Effects Increased risk of urinary tract infections (UTIs) Glucosuria (leading to UTIs and vulvovaginal candidiasis) Dehydration (orthostatic hypotension) Weight loss Contraindications Not recommended if estimated glomerular filtration rate (eGFR) < 45 ml/min Use with caution in renal insufficiency (decreased efficacy with decreased GFR) The other options (Option A, C, and D) do not carry this specific contraindication. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3113.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 9,
      "question": "A 68-year-old woman with a history of type 2 diabetes comes for a follow-up on her blood sugar management. She reports that her current regimen is not helping to control her levels. She has a medical history of osteoporosis for which she takes calcium and vitamin D supplements and has well-controlled hypertension. Which of the following medications is contraindicated for her?",
      "options": {
        "A": "Metformin",
        "B": "Pioglitazone",
        "C": "Sitagliptin",
        "D": "Glipizide"
      },
      "correct_answer": "B",
      "explanation": "its association with an increased risk of fractures. Drug Class Thiazolidinediones (TZDs) Examples Pioglitazone Rosiglitazone Mechanism of Action Decrease insulin resistance by binding to peroxisomal proliferator-activated receptor gamma (PPAR- γ ) Increases insulin sensitivity and levels of adiponectin; regulates glucose metabolism and fatty acid storage Indications Type 2 Diabetes Mellitus (T2DM) Polycystic Ovary Syndrome (PCOS) Side Effects Weight gain Edema Heart failure Increased risk of fractures Pioglitazone: Increased risk of bladder cancer Rosiglitazone: Increased risk of myocardial infarction (MI) and cardiovascular death Contraindications Hepatic failure Congestive heart failure (NYHA Grade III/IV) Worsening of diabetic macular edema Increased fracture risk in postmenopausal women The other options (Option A, C, and D): are generally safer for patients with their medical background. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3112",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 10,
      "question": "A 55-year-old woman with type 2 diabetes is being educated about her new medication, a meglitinide, to help manage her blood sugar levels. The doctor discusses the characteristics of this class of medications. Which of the following statements is incorrect regarding this drug class?",
      "options": {
        "A": "They are weight neutral",
        "B": "Acts on ATP-sensitive potassium channels",
        "C": "Hypoglycemia is a potential side effect",
        "D": "They are secretagogues"
      },
      "correct_answer": "A",
      "explanation": "statement A incorrect. Drug Class Meglitinides They are Secretagogues but not sulphonylureas (Option D) Examples Repaglinide Nateglinide Mechanism of Action Same as sulphonylureas Acts on ATP-sensitive potassium channels (Option B) Promotes insulin release (shorter acting) Side Effects Hypoglycemia (Option C) Weight gain Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC7389480/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 11,
      "question": "A 40-year-old male with type 1 diabetes presents with consistently elevated blood glucose levels in the early morning. He denies any nocturnal hypoglycemia. His current insulin regimen includes twice-daily intermediate-acting insulin. Which of the following is the most likely explanation for his fasting hyperglycaemia?",
      "options": {
        "A": "Nocturnal hypoglycemia followed by rebound hyperglycemia",
        "B": "Increased insulin sensitivity between midnight and 2 am",
        "C": "Increased secretion of cortisol and growth hormone during the night",
        "D": "Insufficient insulin administration at bedtime"
      },
      "correct_answer": "C",
      "explanation": "increased secretion of cortisol and growth hormone without preceding nocturnal hypoglycemia. Dawn Phenomenon vs Somogyi Phenomenon: Feature Dawn Phenomenon Somogyi Phenomenon Definition Fasting hyperglycaemia in the early morning due to natural circadian hormone release. Rebound hyperglycemia after nocturnal hypoglycemia due to counterregulatory hormone release. (Option A ruled out) Cause Increased release of growth hormone and cortisol in the late night hours. Body's response to late-night hypoglycaemia by releasing adrenaline, glucagon, and cortisol. Hormonal Involvement Hormones oppose insulin, leading to higher glucose levels without prior hypoglycaemia. Counterregulatory hormones stimulate gluconeogenesis and glycogenolysis, raising blood glucose after hypoglycemia. Timing Happens between 5 am - 7 am due to circadian rhythms and insufficient insulin. Occurs after midnight, following hypoglycaemia, leading to elevated morning blood glucose levels. Clinical Relevance Requires adjusting insulin doses and timing to prevent early morning hyperglycemia. Early morning hyperglycemia was once thought to be due to prior hypoglycaemia, but new research questions this theory. Increased insulin sensitivity between midnight and 2 am (Option B): Insulin sensitivity typically decreases due to hormonal changes. Insufficient insulin administration at bedtime (Option D): While it may contribute, the main cause is hormonal changes during the early morning.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 12,
      "question": "A 62-year-old male with a history of type 2 diabetes mellitus presents with a sore throat, nasal congestion, and a persistent cough. What is the drug's mechanism of action responsible for this patient's symptoms? γ to improve insulin sensitivity",
      "options": {
        "A": "Inhibits the breakdown of GLP-1",
        "B": "Blocks reabsorption of glucose in the PCT",
        "C": "Activates PPAR-",
        "D": "Inhibits intestinal alpha-glucosidases"
      },
      "correct_answer": "A",
      "explanation": "nasopharyngitis, which is a known side effect of DPP-4 inhibitors. DPP-4 inhibitors, such as sitagliptin, inhibit the enzyme DPP-4, leading to increased levels of GLP-1. This enhances insulin secretion and decreases glucagon release. Drug Class DPP-4 Inhibitors (“-glips”) Examples Sitagliptin Saxagliptin Linagliptin Mechanism of Action (MOA) Inhibits DPP-4 → decreases degradation of native GLP-1 → decreases glucagon release → decreases gastric emptying → increases glucose-dependent insulin release Indications Lower rates of hypoglycemia Weight neutral Safe in hepatic insufficiency Side Effects Respiratory infections (Nasopharyngitis) Urinary infections Weight neutral Increases satiety (often desired) Contraindications Renal failure (except Linagliptin) Blocks reabsorption of glucose in the proximal convoluted tubule (Option B): This mechanism refers to SGLT2 inhibitors, which do not cause nasopharyngitis. Activates PPAR- γ to improve insulin sensitivity (Option C): This is associated with thiazolidinediones, which are unrelated to respiratory symptoms. Inhibits intestinal alpha-glucosidases (Option D) : This mechanism describes alpha-glucosidase inhibitors, primarily affecting carbohydrate absorption and not respiratory infections. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3111",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 13,
      "question": "A 58-year-old male with a history of type 2 diabetes presents with severe abdominal pain radiating to his back, nausea, and vomiting. His labs show elevated amylase levels. What is the drug's mechanism of action that may have contributed to this patient's condition? γ to improve insulin sensitivity",
      "options": {
        "A": "Inhibits hepatic gluconeogenesis",
        "B": "Blocks reabsorption of glucose in PCT",
        "C": "Increases glucose-dependent insulin secretion",
        "D": "Activates PPAR-"
      },
      "correct_answer": "C",
      "explanation": "GLP-1 receptor agonists. GLP-1 receptor agonists enhance glucose-dependent insulin secretion from pancreatic beta cells in response to elevated blood glucose levels, effectively lowering blood sugar. They also inhibit glucagon release, which normally raises blood glucose levels, and slow gastric emptying, promoting increased satiety and often leading to weight loss. Drug Class GLP-1 Receptor Agonists (GLP1RAs) Examples Exenatide Liraglutide Lixisenatide Semaglutide (available as a once-weekly injection and oral preparation) Mechanism of Action (MOA) Decreases glucagon release Decreases gastric emptying Increases glucose-dependent insulin release Indications Delayed gastric emptying, induces early satiety (weight loss) Stabilizes atherosclerotic plaque (reduction in cardiovascular mortality) Side Effects Nausea Vomiting Pancreatitis FDA Black Box Warning Increased risk of thyroid C-cell tumors in rats Contraindications Medullary carcinoma of the thyroid Multiple endocrine neoplasias (MEN) Inhibits hepatic gluconeogenesis (Option A): This mechanism is associated with metformin, which does not typically cause pancreatitis. Blocks reabsorption of glucose in PCT (Option B): This refers to SGLT2 inhibitors, which also have no direct link to pancreatitis. Activates PPAR- γ to improve insulin sensitivity (Option D): This mechanism is related to thiazolidinediones, which are not known to cause pancreatitis. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3110",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 14,
      "question": "A 50-year-old female with Type 2 diabetes has struggled with uncontrolled blood sugar levels for several years and has been reluctant to start medications. However, during her recent visit, she expresses a desire to begin medications. On further evaluation, her lab results are as follows: eGFR: 25 mL/min Random Plasma Glucose: 286 mg/dl HbA1c: 11.2 % Urine glucose ++ She is currently managing her diabetes through dietary changes and lifestyle modifications. What is the most appropriate course of action regarding the initiation of metformin in this patient?",
      "options": {
        "A": "Initiate metformin at a reduced dose",
        "B": "Metformin is contraindicated in this patient",
        "C": "Start metformin with close monitoring of renal function",
        "D": "Initiate metformin at a high dose as HbA1c is very high"
      },
      "correct_answer": "B",
      "explanation": "to the increased risk of lactic acidosis. Biguanides Mechanism of action ↓ Hepatic glucose production ↑ insulin sensitivity Example Metformin Reduction in HBA1C 1–2 % Advantages Weight neutral No risk of hypoglycemia Inexpensive Decreases cardiovascular events Disadvantages Diarrhea Nausea Lactic acidosis Vitamin B12 deficiency Contraindications Renal insufficiency (GFR < 30 mL/min) Congestive heart failure Radiographic contrast studies Hospitalized patients (nil per mouth) Acidosis Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3110",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 15,
      "question": "A 50-year-old man with Type 1 diabetes is currently using NPH insulin for his basal needs but struggles with hypoglycemia during the night. After a review of his regimen, the physician suggests switching to a peakless long-acting insulin. Which insulin would be most appropriate for him?",
      "options": {
        "A": "Insulin glulisine",
        "B": "Insulin glargine",
        "C": "Insulin aspart",
        "D": "Inhaled human insulin"
      },
      "correct_answer": "B",
      "explanation": "coverage without significant risk for nocturnal hypoglycemia. Properties of Insulin Preparations Preparation Time of Action Onset, h Peak, h Effective Duration, h Long-acting Degludec (peakless longest acting) 1-9 - 42 Detemir (peakless insulin) 1-4 - 12-24 Glargine (peakless insulin) (Option B) 2-4 - 20-24 NPH (Intermediate-acting) 2-4 4-10 10-16 Short-acting Aspart (rapid) (Option C ruled out) <0.25 0.5-1.5 3-5 Glulisine (rapid) (Option A ruled out) <0.25 0.5-1.5 3-5 Lispro (rapid) <0.25 0.5-1.5 3-5 Regular 0.5-1.0 2-3 4-8 Inhaled human insulin (rapid) (Afrezza) (Option D ruled out) <0.5 1-2 3 Reference: Harrison’s Principle of Internal Medicine, Edition 21st- Page 3108, 3106.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 16,
      "question": "A 58-year-old female patient with Type 2 diabetes has been on a basal-bolus insulin regimen consisting of glargine and aspart for the past six months. She reports in her follow-up that her fasting blood glucose levels are around 110 mg/dL, and her postprandial levels are above 200 mg/dL for the past 2 weeks. Which of the following adjustments would be most appropriate for her management?",
      "options": {
        "A": "Reduce the aspart dose and maintain the glargine dose",
        "B": "Increase the dosage of glargine with meals",
        "C": "Increase the aspart dose with meals",
        "D": "No changes needed in the dosage"
      },
      "correct_answer": "C",
      "explanation": "of aspart (rapid-acting bolus insulin) will help cover the carbohydrate intake during meals and improve postprandial glucose control. Basal bolus regimen It is the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal Insulin (Long-acting insulin): Provides a steady insulin supply throughout the day and night to control fasting glucose levels. Administered once or twice daily. Examples: Glargine, Detemir, Degludec. Bolus Insulin (Rapid- or short-acting insulin): Administered at mealtimes to control the rise in blood glucose after eating Examples: Aspart, Lispro, Glulisine, Regular Insulin. Dose is adjusted based on the carbohydrate content of the meal and current blood glucose level. Advantage: Mimics physiological insulin secretion Tight glucose control, reduces the risk of both hyperglycemia and hypoglycemia Used in both type 1 diabetes and type 2 diabetes Disadvantage: Requires frequent blood glucose monitoring to adjust insulin doses Can be complex and requires motivation for adherence Needs extensive patient education Bolus Regimen\" data-author=\"Edelman, Steven & Dailey, George & Flood, Thomas & Kuritzky, Louis & Renda, Susan.\" data-hash=\"8481\" data-license=\"CC BY 2.0\" data-source=\"https://www.researchgate.net/figure/Basal-prandial-ins ulin-replacement-profiles-using-A-NPH-plus-regular-human-insulin-and_fig3_6381071\" data-tags=\"April2025\" height=\"571\" src=\"https://image.prepladder.com/notes/er9f1KF6az51j62JRwLB1744283890.png\" width=\"800\" /> Reduce the aspart dose and maintain the glargine dose (Option A): Reducing the bolus insulin (aspart) would likely worsen her postprandial hyperglycemia, as she already has elevated postprandial levels. Thus the option is incorrect. Increase the dosage of glargine with meals (Option B): Increasing the basal insulin (glargine) will not directly address postprandial hyperglycemia, as basal insulin is meant to control blood glucose levels throughout the day and night. This adjustment could lead to more hypoglycemia during fasting periods without sufficiently managing the elevated postprandial levels. Thus the option is incorrect. No changes needed in the dosage (Option D): Continuous hyperglycemia indicates the need for a reevaluation and adjustment of her insulin regimen. Thus the option is incorrect. Reference: Insulin- Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy - Endotext - NCBI Bookshelf (nih.gov) Harrison’s Principle of Internal Medicine, 21st Edition, Page 3108, 3109",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 17,
      "question": "A 55-year-old man with T2DM is brought to the emergency department by his family after being found confused and lethargic. He is unable to take oral glucose. His blood glucose is 40 mg/dL. The medical team administers IV glucose, but his glucose levels drop again despite repeated boluses. He is on sulfonylurea medication for diabetes. Which of the following is the next best step in management?",
      "options": {
        "A": "Administer subcutaneous glucagon",
        "B": "Start a continuous glucose infusion",
        "C": "Administer oral glucose",
        "D": "Administer octreotide"
      },
      "correct_answer": "D",
      "explanation": "which IV glucose alone may not address. Hypoglycemia treatment Oral Treatment: (Option C ruled out) For conscious patients 15-20 grams of glucose (e.g., glucose tablets, sugary drinks, candy, or food) Parenteral Treatment: Confused or unconscious patient unable to take food/drink IV glucose 25 grams, followed by a glucose infusion while checking blood sugar levels regularly Injection Glucagon: If IV glucose isn’t possible, subcutaneous (SC) or intramuscular (IM) glucagon (1.0 mg for adults), especially in Type 1 Diabetes (T1DM) Note: Glucagon won’t work well in people with depleted glycogen (e.g., alcohol-induced hypoglycemia). Limitations of Glucagon: In Type 2 Diabetes (T2DM), glucagon is less effective because it also stimulates insulin release. (Option A ruled out) Octreotide (Somatostatin Analogue) can be used to stop excess insulin secretion in cases of sulfonylurea-induced hypoglycemia. (Option D) Start a continuous glucose infusion (Option B): It can help maintain blood glucose levels but does not address the underlying cause of the recurrent hypoglycemia, which is likely due to the effects of the sulfonylurea in this case. Therefore, it's not the immediate next best step. Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3134, 3135.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 18,
      "question": "Continuous Glucose Monitoring (CGM) was recently initiated in a 28-year-old woman with longstanding T1DM. During her follow-up appointment, she inquired about estimating her HbA1c from the CGM system. Which CGM metric provides an estimate of her average glucose level and correlates with her A1C?",
      "options": {
        "A": "Time in Range (TIR)",
        "B": "Hypoglycemia time",
        "C": "Glucose Management Indicator (GMI)",
        "D": "Ambulatory Glucose Profile (AGP)"
      },
      "correct_answer": "C",
      "explanation": "level based on CGM data and correlates it with the patient’s HbA1c. Continuous blood glucose monitoring system A sensor is used to measure glucose levels in the interstitial fluid, which is in balance with blood glucose, though there may be a delay when blood glucose changes rapidly . Two Approaches: Glucose levels are continuously monitored. Glucose levels are recorded only when a detector is placed over the sensor. Sensor Placement: Glucose sensors are inserted under the skin (subcutaneously) and need to be replaced every 3 to 14 days. Application: Time in Range (TIR): Percentage of time blood sugar stays within a target range. (Option A ruled out) Ambulatory Glucose Profile: A visual summary of glucose data. (Option D ruled out) Hypoglycemia time: Time spent with dangerously low blood sugar. (Option B ruled out) Glucose Management Indicator (GMI): Estimates average blood sugar and correlates with A1C levels (long-term blood sugar control). (Option C) Benefits: Tracking glucose trends and changes, predicting and preventing both high (hyperglycemia) and low (hypoglycemia) blood sugar. Type 1 Diabetes: Particularly beneficial for those with hypoglycemia unawareness, especially at night. Automated Insulin Delivery: When combined with an insulin pump, CGM can adjust insulin delivery based on glucose levels using predictive algorithms to prevent hypoglycemia or maintain stable glucose levels (closed-loop control). Insulin Delivery \" data-author=\"Sjö\" data-hash=\"8479\" data-license=\"CC BY-SA 4.0\" data-source=\"https://commons.wikimedia.org/wiki/File:BGM_twopart.JPG\" data-tags=\"April2025\" height=\"212\" src=\"https://image.prepladder.com/notes/92XnLYN8M0MgYxqCHMp71744283839.png\" width=\"296\" /> glucose monitoring in children with type 1 diabetes. International journal of pediatric endocrinology. 2013. 8. 10.1186/1687-9856-2013-8. \" data-hash=\"8480\" data-license=\"CC BY 2.0\" data-source=\"https://www.researchgat e.net/figure/CGM-summary-graph-for-case-2-Asymptomatic-hypoglycemia-was-identified-overnight_fig4_23608 3013\" data-tags=\"April2025\" src=\"https://image.prepladder.com/notes/BPVtnNkvSsTe1a8yZumo1744283868.png\" /> Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3106",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    },
    {
      "q_no": 19,
      "question": "A 12-year-old girl with T1DM is transitioning to an insulin pump. Her doctor explains that the pump delivers continuous insulin to meet basal needs. What type of insulin is typically used for basal delivery in insulin pump therapy?",
      "options": {
        "A": "Long-acting insulin",
        "B": "Intermediate-acting insulin",
        "C": "Rapid-acting insulin",
        "D": "Both A and C"
      },
      "correct_answer": "C",
      "explanation": "and bolus needs. The pump delivers a steady, continuous dose of basal insulin and allows bolus doses to be administered before meals. T1DM management Lifestyle modifications Physical activity Carbohydrate counting helps with accurate insulin dosing before meals Blood Glucose Monitoring Glucose meters: Patients should check blood sugar at least 4 times daily (before meals and at bedtime) Continuous Glucose Monitors (CGMs): Provide real-time glucose readings and alerts for hypoglycemia/hyperglycemia Diabetes Self-Management Education and Support (DSMES) Improve the patient’s knowledge, skills, and abilities necessary for diabetes self-care Addressing psychosocial issues and emotional well-being Lifelong Insulin Replacement Multiple Daily Injections (MDI) Combines basal insulin (long-acting , once or twice daily) and bolus insulin ( rapid-acting before meals). (Option A ruled out) Continuous Subcutaneous Insulin Infusion (CSII) / Insulin Pump Delivers continuous rapid-acting insulin for basal needs with boluses for meals via a pump. (Option C) Some pumps connect to Continuous Glucose Monitors (CGMs) and automatically adjust insulin based on blood sugar levels (hybrid closed-loop systems). Intermediate-acting insulin (Option B): It is not used in insulin pumps and is typically used in older basal-bolus regimens. It has a peak effect that can make glucose control less predictable. Hence, this option is incorrect. Reference: Type 1 Diabetes - StatPearls - NCBI Bookshelf (nih.gov) Harrison’s Principle of Internal Medicine, 21st Edition, Page 3104 - 3107",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Endocrinology-Diabetes Mellitus-Ii"
    }
  ]
}
